Page 1922 - Williams Hematology ( PDFDrive )

1896 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1897

732. Adelman B, et al: Plasmin effect on platelet glycoprotein Ib-von Willebrand factor 765. Altieri DC, Plescia J, Plow EF: The structural motif glycine 190-valine 202 of the
interactions. Blood 64:32–40, 1985. fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2,
733. Adnot S, et al: Plasmin: A possible physiological modulator of human platelet adeny- Mac-1) and promotes leukocyte adhesion. J Biol Chem 268(3):1847–1853, 1993.
late cyclase system. Clin Sci 72:467–473, 1987. 766. Silverstein RL, Asch AS, Nachman RL: Glycoprotein IV mediates thrombospond-
734. Federici AB, et al: Proteolysis of von Willebrand factor in patients undergoing throm- in-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 84:
bolytic therapy. Circulation 78(Suppl.II):II–120-(Abs). 546–552, 1989.
735. Gimple LW, et al: Correlation between template bleeding times and spontaneous 767. Santoso S, et al: The junctional adhesion molecule 3 (JAM-3) on human platelets is a
bleeding during treatment of acute myocardial infarction with recombinant tissue- counterreceptor for the leukocyte integrin Mac-1. J Exp Med 196(5):679–691, 2002.
type plasminogen activator. Circulation 80:581–588, 1988, 1989. 768. Marcus AJ, Safier LB: Thromboregulation: Multicellular modulation of platelet reac-
736. Johnstone MT, et al: Bleeding time prolongation with streptokinase and its reduction tivity in hemostasis and thrombosis. FASEB J 7(6):516–522, 1993.
with 1- desamino-8-D-arginine vasopressin. Circulation 82(6):2142–2151, 1990. 769. Lindemann S, et al: Activated platelets mediate inflammatory signaling by regulated
737. Kamat SG, Schafer AI: Antiplatelet effects of fibrinolytic agents: A potential contribu- interleukin 1beta synthesis. J Cell Biol 154(3):485–490, 2001.
tor to the hemostatic defect after thrombolysis. Coron Artery Dis 6(12):930–935, 1995. 770. Alderson MR, et al: CD40 expression by human monocytes: Regulation by cytokines
738. Kowalski E, Kopec M, Wegrzynowicz Z: Influence of fibrinogen degradation prod- and activation of monocytes by the ligand for CD40. J Exp Med 178(2):669–674, 1993.
ucts (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thromb 771. Henn V, et al: CD40 ligand on activated platelets triggers an inflammatory reaction of
Diath Haemorrh 10:406–423, 1963. endothelial cells. Nature 391(6667):591–594, 1998.
739. Loscalzo J, Vaughan DE: Tissue plasminogen activator promotes platelet disaggrega- 772. Yellin MJ, et al: Functional interactions of T cells with endothelial cells: The role of
tion in plasma. J Clin Invest 79:1749–1754, 1987. CD40L-CD40-mediated signals. J Exp Med 182(6):1857–1864, 1995.
740. Michelson AD, et al: Effect of in vivo infusion of recombinant tissue-type plasmino- 773. Slupsky JR, et al: Activated platelets induce tissue factor expression on human umbil-
gen activator on platelet glycoprotein Ib. Thromb Res 60(5):421–424, 1990. ical vein endothelial cells by ligation of CD40. Thromb Haemost 80(6):1008–1014,
741. Schafer AL, Adelman B: Plasmin inhibition of platelet function and of arachidonic 1998.
acid metabolism. J Clin Invest 75:456–461, 1985. 774. Del PD, et al: The plasma membrane redox system in human platelet functions and
742. Schafer AL, et al: Synergistic inhibition of platelet activation by plasmin and pros- platelet-leukocyte interactions. Thromb Haemost 101(2):284–289, 2009.
taglandin I2. Blood 69:1504–1507, 1987. 775. Goel MS, Diamond SL: Neutrophil enhancement of fibrin deposition under flow
743. Shin Y, et al: Binding of von Willebrand factor cleaving protease ADAMTS13 to through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc
Lys-plasmin(ogen). J Biochem 152(3):251–258, 2012. Biol 21(12):2093–2098, 2001.
744. Tersteeg C, et al: Plasmin cleavage of von Willebrand factor as an emergency bypass 776. Goel MS, Diamond SL: Neutrophil cathepsin G promotes prothrombinase and fibrin
for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 129(12): formation under flow conditions by activating fibrinogen-adherent platelets. J Biol
1320–1331, 2014. Chem 278(11):9458–9463, 2003.
745. Coller BS: Binding of abciximab to α β and activated α β receptors: With a review of 777. Giesen PL, et al: Blood-borne tissue factor: Another view of thrombosis. Proc Natl
M 2
V 3
platelet-leukocyte interactions. Thromb Haemost 82(2):326–336, 1999. Acad Sci U S A 96(5):2311–2315, 1999.
746. Farb A, et al: Pathology of acute and chronic coronary stenting in humans. Circulation 778. Furie B, Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus
99(1):44–52, 1999. formation. Trends Mol Med 10(4):171–178, 2004.
747. Merhi Y, et al: Selectin blockade reduces neutrophil interaction with platelets at 779. Pluskota E, et al: Expression, activation, and function of integrin alphaMbeta2
the site of deep arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol (Mac-1) on neutrophil-derived microparticles. Blood 112(6):2327–2335, 2008.
19(2):372–377, 1999. 780. Andre P, et al: Pro-coagulant state resulting from high levels of soluble P-selectin in
748. Smyth SS, et al: β3-integrin-deficient mice, but not P-selectin-deficient mice, develop blood. Proc Natl Acad Sci U S A 97(25):13835–13840, 2000.
intimal hyperplasia after vascular injury: Correlation with leukocyte recruitment to 781. Hrachovinova I, et al: Interaction of P-selectin and PSGL-1 generates microparticles
adherent platelets 1 hour after injury. Circulation 103:2501–2507, 2001. that correct hemostasis in a mouse model of hemophilia A. Nat Med 9(8):1020–1025,
749. Wehner J, et al: Antibody and complement in transplant vasculopathy. Circ Res 2003.
100(2):191–203, 2007. 782. Ott I, et al: Increased neutrophil-platelet adhesion in patients with unstable angina.
750. Nishimura S, et al: In vivo imaging in mice reveals local cell dynamics and inflamma- Circulation 94(6):1239–1246, 1996.
tion in obese adipose tissue. J Clin Invest 118(2):710–721, 2008. 783. Mickelson JK, et al: Leukocyte activation with platelet adhesion after coronary angio-
751. Bozza FA, et al: Amicus or adversary: Platelets in lung biology, acute injury, and plasty: A mechanism for recurrent disease? J Am Coll Cardiol 28(2):345–353, 1996.
inflammation. Am J Respir Cell Mol Biol 40(2):123–134, 2009. 784. Michelson AD, et al: Circulating monocyte-platelet aggregates are a more sensi-
752. Schober A, et al: Deposition of platelet RANTES triggering monocyte recruitment tive marker of in vivo platelet activation than platelet surface P-selectin: Studies in
requires P-selectin and is involved in neointima formation after arterial injury. Circu- baboons, human coronary intervention, and human acute myocardial infarction. Cir-
lation 106(12):1523–1529, 2002. culation 104(13):1533–1537, 2001.
753. von Hundelshausen P, et al: RANTES deposition by platelets triggers monocyte 785. Bugert P, et al: The variable number of tandem repeat polymorphism in the P-selectin
arrest on inflamed and atherosclerotic endothelium. Circulation 103(13):1772–1777, glycoprotein ligand-1 gene is not associated with coronary heart disease. J Mol Med
2001. (Berl) 81(8):495–501, 2003.
754. Huo Y, et al: Circulating activated platelets exacerbate atherosclerosis in mice deficient 786. Diz-Kucukkaya R, et al: P-selectin glycoprotein ligand-1 VNTR polymorphisms
in apolipoprotein E. Nat Med 9(1):61–67, 2003. and risk of thrombosis in the antiphospholipid syndrome. Ann Rheum Dis 66(10):
755. Diacovo TG, et al: Neutrophil rolling, arrest, and transmigration across activated, 1378–1380, 2007.
surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin 787. Lozano ML, et al: Polymorphisms of P-selectin glycoprotein ligand-1 are associated
CD11b/CD18. Blood 88(1):146–157, 1996. with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. Br J
756. Hamburger SA, McEver RP: GMP-140 mediates adhesion of stimulated platelets to Haematol 115(4):969–976, 2001.
neutrophils. Blood 75(3):550–554, 1990. 788. Ozben B, et al: The association of P-selectin glycoprotein ligand-1 VNTR polymor-
757. Kirchhofer D, Riederer MA, Baumgartner HR: Specific accumulation of circulating phisms with coronary stent restenosis. J Thromb Thrombolysis 23(3):181–187, 2007.
monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular 789. Roldan V, et al: Short alleles of P-selectin glycoprotein ligand-1 protect against prema-
injury model. Blood 89(4):1270–1278, 1997. ture myocardial infarction. Am Heart J 148(4):602–605, 2004.
758. Konstantopoulos K, et al: Venous levels of shear support neutrophil-platelet adhesion 790. Tauxe C, et al: P-selectin glycoprotein ligand-1 decameric repeats regulate selectin-
and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation dependent rolling under flow conditions. J Biol Chem 283(42):28536–28545, 2008.
98(9):873–882, 1998. 791. Wang Y, et al: Platelet-derived S100 family member myeloid-related protein-14 regu-
759. Larsen E, et al: PADGEM protein: A receptor that mediates the interaction of acti- lates thrombosis. J Clin Invest 124(5):2160–2171, 2014.
vated platelets with neutrophils and monocytes. Cell 59(2):305–312, 1989. 792. Clark SR, et al: Platelet TLR4 activates neutrophil extracellular traps to ensnare bacte-
760. Sheikh S, Nash GB: Continuous activation and deactivation of integrin CD11b/CD18 ria in septic blood. Nat Med 13(4):463–469, 2007.
during de novo expression enables rolling neutrophils to immobilize on platelets. 793. Geddings JE, Mackman N: New players in haemostasis and thrombosis. Thromb Hae-
Blood 87(12):5040–5050, 1996. most 111(4):570–574, 2014.
761. Yeo EL, Sheppard JA, Feuerstein IA: Role of P-selectin and leukocyte activation in 794. Martinod K, Wagner DD: Thrombosis: Tangled up in NETs. Blood 123(18):
polymorphonuclear cell adhesion to surface adherent activated platelets under physi- 2768–2776, 2014.
ologic shear conditions (an injury vessel wall model). Blood 83(9):2498–2507, 1994. 795. Arman M, et al: Amplification of bacteria-induced platelet activation is triggered
762. Gear AR, Camerini D: Platelet chemokines and chemokine receptors: Linking hemo- by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. Blood 123(20):
stasis, inflammation, and host defense. Microcirculation 10(3–4):335–350, 2003. 3166–3174, 2014.
763. Weber C, Springer TA: Neutrophil accumulation on activated, surface-adherent plate- 796. Boudreau LH, et al: Platelets release mitochondria serving as substrate for bacteri-
lets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIb- cidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 124(14):
beta3 and stimulated by platelet-activating factor. J Clin Invest 100(8):2085–2093, 2173–2183, 2014.
1997. 797. Sun H, et al: Reduced thrombin generation increases host susceptibility to group A
764. Romo GM, et al: The glycoprotein Ib-IX-V complex is a platelet counterreceptor for streptococcal infection. Blood 113(6):1358–1364, 2009.
P-selectin. J Exp Med 190(6):803–814, 1999. 798. Li N, Platelet-lymphocyte cross-talk. J Leukoc Biol 83(5):1069–1078, 2008.

Kaushansky_chapter 112_p1829-1914.indd 1897 17/09/15 3:30 pm